

Contents

Chapter 1 The Role of Backbone Modifications in Oligonucleotide-Based Strategies

Jens Kurreck

1.1	Introduction	1
1.2	Antisense Oligonucleotides	3
1.2.1	Phosphorothioates	4
1.2.2	2'- <i>O</i> -Methyl and 2'- <i>O</i> -Methoxyethyl Ribonucleotides	5
1.2.3	Locked Nucleic Acids, Phosphorodiamidate Morpholino Oligomers and N3' → P5' Phosphoramidates	7
1.3	Ribozymes	8
1.4	Small Interfering RNAs	11
1.4.1	Introduction of Modified Nucleotides	12
1.4.2	Combination of Different Modifications	13
1.4.3	Terminal Modifications	14
1.5	Aptamers and Decoy Oligonucleotides	15
1.6	Concluding Remarks	18
	Acknowledgement	18
	References	18

Chapter 2 Genasense (G3139): An Antisense Bcl-2 Oligodeoxyribonucleotide with Substantial Clinical Activity and a Complex Mechanism of Action

Cy A. Stein, Noah Kornblum, Johnathan Lai and Luba Benimetskaya

2.1	Early Studies on G3139	23
2.2	G3139 in Melanoma: Clinical and Preclinical Results	25

2.3	The Role of Bcl-2 in Melanoma	27
2.4	G3139 Causes Bcl-2 Independent Apoptosis in Melanoma Cells	28
2.5	Clinical Trials in Advanced Melanoma	32
2.6	Safety and Tolerability	37
2.7	Conclusion	39
	In Memoriam Aeternam	39
	References	39

Chapter 3 Antisense Morpholino Oligomers and Their Peptide Conjugates

Hong M. Moulton and Jon D. Moulton

3.1	Introduction	43
3.1.1	What is a Morpholino?	43
3.1.1.1	Nomenclature and Chemical Structure	43
3.1.1.2	Preparation	44
3.1.1.3	Solubility and Stability	46
3.1.2	Mechanism of Action	46
3.1.2.1	Blocking Translation	46
3.1.2.2	Modifying Splicing	47
3.1.2.3	Blocking MicroRNA	48
3.1.2.4	Blocking Other RNA Sites – Splice Regulation Sequences, Ribozymes, Slippery Sequences	49
3.2	Research Applications of Morpholinos	49
3.2.1	Morpholinos for Developmental Biology	49
3.2.2	Morpholinos for Studying Diseases: Genetic Disorders, Infection, Cancer, Trauma and Toxins	49
3.2.2.1	Genetic Disorders	49
3.2.2.2	Infection	50
3.2.2.3	Cancer	52
3.2.2.4	Trauma and Toxins	53
3.2.3	Methods for Delivery of Morpholinos	54
3.2.3.1	Microinjection and Electroporation	54
3.2.3.2	Reagent-based Methods: Endo-Porter and Ethoxylated Polyethylenimine	54
3.2.3.3	Particle-based Methods	55
3.3	Cell-penetrating Peptide–Morpholino Conjugates	55
3.3.1	Chemistry	56
3.3.2	Internalization Mechanism	56
3.3.3	Effects of CPP Sequences on PPMO Efficacy	58
3.3.4	Specificity	59

<i>Contents</i>	xi
3.3.5 Stability	59
3.3.6 Applications	60
3.3.6.1 Genetic Disorders	60
3.3.6.2 Viral and Bacterial Infections	64
3.3.7 Toxicity	67
3.4 Therapeutic Applications of Morpholinos and Peptide–Morpholino Conjugates	70
3.4.1 Cardiovascular Trials	70
3.4.1.1 AVI-4126	70
3.4.1.2 AVI-5126	70
3.4.2 Genetic Disease Trial	71
3.4.2.1 AVI-4658	71
3.5 Conclusion	71
Acknowledgements	71
References	71

Chapter 4 Peptide–Peptide Nucleic Acid Conjugates for Modulation of Gene Expression

Martin M. Fabani, Gabriela D. Ivanova and Michael J. Gait

4.1 Steric Block as a Method of Gene Expression Control	80
4.2 Peptide Nucleic Acids in Comparison with Other Steric Block Oligomer Types	81
4.3 Cellular Delivery: The Promise of Cell Penetrating Peptides	83
4.4 Synthesis of Peptide–PNA Conjugates	85
4.4.1 Continuous Synthesis	85
4.4.2 Fragment Conjugation	86
4.5 Steric Block Biological Activities of Peptide–PNA Conjugates	88
4.6 Towards <i>in vivo</i> Therapeutic Applications	96
Acknowledgements	97
References	97

Chapter 5 Locked Nucleic Acid: Properties and Therapeutic Aspects

*Troels Koch, Christoph Rosenbohm, Henrik F. Hansen,
Bo Hansen, Ellen Marie Straarup and Sakari Kauppinen*

5.1 Introduction	103
5.2 Basic Properties of Locked Nucleic Acids	104
5.2.1 LNA–RNA Hybrid Structure	105
5.2.2 Hybridization Properties	106
5.2.3 Thermodynamic and Kinetic Considerations	109

5.2.4	Biochemical Properties	109
5.2.4.1	General Design of LNA	109
5.2.4.2	Nuclease Resistance	110
5.2.4.3	RNase H Recruitment of LNA	111
5.3	Synthesis of Amidites and Active Pharmaceutical Ingredients	111
5.3.1	Synthesis of Locked Nucleic Acids Phosphoramidites	112
5.3.2	Synthesis of Locked Nucleic Acids Oligonucleotides	115
5.4	Pharmacological Aspects of Locked Nucleic Acid Oligonucleotides Targeting Messenger RNA and MicroRNA	116
5.4.1	Biodistribution of Locked Nucleic Acid Oligonucleotides	116
5.4.2	Inhibition of Messenger RNA Targets	118
5.4.2.1	Targeting Apolipoprotein B-100	118
5.4.2.2	Targeting Survivin	122
5.4.2.3	Targeting Hypoxia-inducible Factor 1 Alpha	123
5.4.2.4	Targeting B-cell Lymphoma 2	124
5.4.3	MicroRNA Targeting with Locked Nucleic Acids	126
5.4.3.1	MicroRNAs in Human Disease	127
5.4.3.2	MicroRNA Targeting Using Locked Nucleic Acid	127
5.4.3.3	<i>In vitro</i> Inhibition of MicroRNA Function Using LNA–AntimiRs	128
5.4.3.4	Antagonizing MicroRNAs for Therapeutics	129
5.5	Clinical Phase I/II Study of SPC2996	130
5.5.1	Clinical Phase I/II Data	131
5.6	Concluding Remarks	133
	Acknowledgements	134
	References	134

Chapter 6 Immune Stimulatory Oligonucleotides

Eugen Uhlmann

6.1	Introduction	142
6.2	Mechanism of Action	143
6.3	TLR9 Activation by CpG Oligonucleotides	146
6.3.1	Classes of CpG Oligonucleotides	146
6.3.2	Chemical Modifications of CpG Oligonucleotides	150

6.3.2.1	Modification of the Internucleotide Phosphodiester Linkage	151
6.3.2.2	Modification of the Heterocyclic Nucleobases	152
6.3.2.3	Modifications of the Sugar Moiety	156
6.4	Therapeutic Applications of CpG Oligonucleotides	157
	Acknowledgements	160
	References	160

Chapter 7 Decoy Oligodeoxynucleotides to Treat Inflammatory Diseases

Markus Hecker, Swen Wagner, Stefan W. Henning and Andreas H. Wagner

7.1	Introduction	163
7.2	Decoy Oligonucleotide Synthesis	164
7.3	Decoy Oligonucleotide Administration	165
7.3.1	Delivery	165
7.3.2	Pharmacokinetics	166
7.3.3	Toxicology	168
7.4	Mechanism of Action	168
7.4.1	Target Identification	169
7.4.2	Target Specificity	170
7.4.3	Sequence Optimization for Cellular Uptake	172
7.4.4	Stability	174
7.5	Therapeutic Applications	174
7.5.1	Asthma	174
7.5.2	Atherosclerosis and Related Vascular Remodelling Processes	176
7.5.3	Inflammatory Skin Disease	178
7.5.4	Rheumatoid Arthritis	181
7.5.5	Acute and Chronic Transplant Rejection	182
7.5.6	Other	183
7.6	Perspective	184
7.6.1	Nucleic Acid Based Drugs in Comparison	184
7.6.2	Clinical Development	185
	References	185

Chapter 8 AS1411: Development of an Anticancer Aptamer

Nigel Courtenay-Luck and Donald M. Miller

8.1	An Introduction to Aptamers	189
8.2	AS1411: An Anticancer Aptamer	190
8.2.1	Nucleolin: An Anticancer Target	191
8.2.2	Anticancer Mechanism of Action of AS1411	192
8.3	<i>In vitro</i> Inhibition of Growth by AS1411	193

8.4	<i>In vivo</i> Biodistribution of AS1411	193
8.5	<i>In vivo</i> Antitumour Activity of AS1411	194
8.6	Preclinical Toxicology of AS1411	196
8.7	Clinical Studies with AS1411	196
8.8	Future Development of AS1411	197
	References	197

Chapter 9 Spiegelmer NOX-E36 for Renal Diseases

*Dirk Eulberg, Werner Purschke, Hans-Joachim Anders,
Norma Selve and Sven Klussmann*

9.1	Spiegelmers: Functional Mirror-Image Oligonucleotides	200
9.1.1	Identification of Spiegelmer Products	201
9.2	MCP-1 and Inflammatory Kidney Diseases	201
9.2.1	The Target: MCP-1 (CCL-2)	201
9.2.1.1	Species Homology	205
9.2.1.2	Pathophysiology of MCP-1	206
9.2.2	Inflammatory Kidney Diseases	207
9.2.2.1	Expression of MCP-1 in Inflamed Kidneys	208
9.2.2.2	Role of MCP-1 in Inflammatory Renal Diseases	208
9.2.2.3	Main Indication: Lupus Nephritis	208
9.3	Identification and Characterization of NOX-E36	209
9.3.1	Path of Selection for NOX-E36	209
9.3.1.1	Biophysical Properties of NOX-E36	210
9.3.1.2	Biophysical Properties of NOX-E36-5'-Polyethyleneglycol (PEG)	210
9.3.2	<i>In vitro</i> Profiling of NOX-E36	211
9.3.2.1	Calcium-Release Assay	212
9.3.2.2	Chemotaxis Assay	213
9.3.2.3	<i>In vitro</i> Activity of NOX-E36-5'-PEG	213
9.3.2.4	Specificity of NOX-E36	213
9.3.2.5	Selectivity of NOX-E36	214
9.3.3	<i>In vivo</i> Efficacy of an Anti-MCP-1 Spiegelmer	215
9.3.3.1	Murine-Specific Spiegelmer: mNOX-E36	216
9.3.3.2	Functional <i>in vitro</i> Profile of Murine-Specific mNOX-E36	216
9.3.3.3	MRL ^{lpr/lpr} Mouse ('Lupus Mouse') – Chronic Progressive Renal Inflammation	217
9.3.3.4	mNOX-E36-3'-PEG Improves Kidney Disease of MRL ^{lpr/lpr} Mice	218
9.3.3.5	mNOX-E36 Treatment Improves Condition of Skin and Eyes	219

9.3.3.6	mNOX-E36-3'-PEG Improves Survival of MRL ^{lpr/lpr} Mice	220
9.4	Summary and Outlook	221
	Acknowledgements	221
	References	221

Chapter 10 Strategies for the Delivery of Oligonucleotides *in vivo*
Christian Reinsch, Evgenios Siepi, Andreas Dieckmann and Steffen Panzner

10.1	Introduction	226
10.2	Degradation and Excretion: Progress with Chemically Modified Oligonucleotides	227
10.2.1	Antisense Oligonucleotides	227
10.2.2	Small Interfering RNAs (siRNAs)	228
10.3	Unassisted Cellular Uptake of Oligonucleotides	228
10.4	Carriers for Oligonucleotide Delivery	230
10.4.1	Cationic Carriers	230
10.4.1.1	CLP-2-Based Liposomes	230
10.4.1.2	Atuplex Technology	230
10.4.1.3	Stable Antisense-Lipid Particles and Stable Nucleic Acid-Lipid Particles	232
10.4.1.4	Cyclodextrin Nanoparticles	233
10.4.1.5	Polyethylenimine-Based Delivery System	233
10.4.1.6	Dendrimer-Based Delivery System	234
10.4.2	Anionic and Neutral Carriers	234
10.4.2.1	Dioleoyl Phosphatidylcholine Liposomes	234
10.4.2.2	Egg-PC-Cholesterol Liposomes	235
10.4.3	Summary of Common Building Principles for Oligonucleotide Carriers	235
10.5	Summary	236
	Acknowledgement	237
	References	237

Chapter 11 Lipid-Mediated *in vivo* Delivery of Small Interfering RNAs
Ian MacLachlan

11.1	Lipid-Mediated Drug Delivery	241
11.2	Liposome Constituents	243
11.2.1	Cationic Lipids	244
11.2.2	Neutral Helper Lipids	245
11.2.3	PEG-Lipids	245

11.3	Methods of Encapsulating Nucleic Acids	246
11.3.1	Passive Encapsulation	247
11.3.2	The Ethanol Drop Method of Encapsulation	247
11.3.3	Encapsulation in Ethanol-Destabilized Liposomes	249
11.3.4	The Spontaneous Vesicle Formation by Ethanol Dilution Method of Encapsulation	250
11.4	Pharmacology of Liposomal Nucleic Acids	251
11.4.1	Pharmacokinetics and Biodistribution of Liposomal siRNAs Following Systemic Administration	251
11.4.2	Toxicity of Liposomal Nucleic Acid Formulations	255
11.4.3	Immune Stimulation	255
11.4.4	Immunogenicity	257
11.4.5	Efficacy of Liposomally Formulated Nucleic Acid Drugs	258
	References	262

Chapter 12 Vector-Mediated and Viral Delivery of Short Hairpin RNAs

Henry Fechner and Jens Kurreck

12.1	Introduction	267
12.2	Plasmid-derived Short Hairpin RNAs	268
12.3	Generation of Transgenic Animals for Knockdown Studies	271
12.4	MicroRNA-type shRNAs	272
12.5	Inducible RNAi Systems	274
12.6	Viral Vectors for Delivery of shRNAs	282
12.6.1	Retrovirus Vectors	282
12.6.2	Adenovirus Vectors	285
12.6.3	Vectors Based on Adeno-associated Viruses	287
12.7	Summary	288
	Acknowledgement	289
	References	289

Chapter 13 Development of an RNAi-Based Gene Therapy against HIV-1

Olivier ter Brake and Ben Berkhout

13.1	Introduction	296
13.2	The HIV-1 Life Cycle	297
13.3	RNA Interference as an Antiviral Strategy	299
13.3.1	Combinatorial RNAi Approach 1: Highly Conserved Targets	300

<i>Contents</i>	xvii
13.3.2 Combinatorial RNAi Approach 2: Second-Generation shRNAs	303
13.3.3 Combinatorial Approach 3: Include Cellular Factors as RNAi Targets	304
13.4 Gene Therapy for HIV-1 Infection	306
13.4.1 Lentiviral Vector Development	308
13.4.2 Preclinical Evaluation: Safety and Efficacy	309
Acknowledgements	311
References	311
Chapter 14 RNA Based Therapies for Treatment of HIV Infection	
<i>Lisa Scherer, Marc S. Weinberg and John J. Rossi</i>	
14.1 Introduction: Challenges to Conventional Therapies	316
14.2 Potential HIV Targets for RNA-based Therapeutics	317
14.2.1 Ribozymes, External Guide Sequences and Aptamers as Therapeutics	318
14.2.2 RNAi Approaches to Inhibit HIV Replication	319
14.3 RNAi-induced Transcriptional Gene Silencing	323
14.4 Delivery of Anti-HIV RNAs to Hematopoietic Cells	324
14.5 Future Prospects	324
References	325
Subject Index	329

